Immuron Ltd (IMRN) 6-K, filed May 13, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2021

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on May 13, 2021 titled:

-	“IMM124E May Offer New Modality for Inhibition of SARS-CoV-2”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

EXHIBITS

Exhibit<br><br>Number	Description
99.1	IMM124E May Offer New Modality for Inhibition of SARS-CoV-2

| 1 |

| --- |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date: May 13, 2021	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

Exhibit 99.1

IMM124E – May offer a New modality forInhibition of SARS-CoV-2

Key Points

●	Monash University Research Update on SARS-CoV-2 program
●	Biomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E
---	---
●	Appointment of Chief Medical Officer with preliminary focus on COVID-19
---	---

Melbourne, Australia, May 13, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on the anti-viral activity of IMM124E used to manufacture the company’s flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn®. Monash University Scientists at the Biomedicine Discovery Institute have developed and optimized two new immunologically based assays utilizing two recombinant reagents, the SARS-CoV-2 Spike protein and a receptor binding domain protein obtained from Melbourne’s Peter Doherty Institute for Infection and Immunity.

Preliminary findings (ASX announcement dated 21 July 2020) previously reported investigating IMM-124E demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19. Further studies now undertaken, by Monash suggest that the SARS-CoV-2 inhibitory activity is novel and does not bind to the spike protein or the receptor binding domain that the virus uses to dock to the cells it infects.

SARS-CoV-2 and Bovine Corona viruses (BCoV) are closely related phylogenetically. Different studies have demonstrated the existence of cross-reactive immunity through shared sites/epitopes between the bovine and human viruses. Thus, it appears that the immunological homology in highly conserved structures between the two viruses may be the cause of the reported inhibition. Immune recognition of viral structural proteins M and S2, by anti-BCoV antibodies present in IMM-124E could cause the inactivation of the SARS-COV-2 virus.

This antiviral effect differs from most Vaccines currently under development which directly target the spike protein. The mode of action may offer a complementary treatment regime using therapeutics targeting the virus.

Level 3, 62 Lygon Street,<br><br> <br>Carlton South, Victoria<br><br> <br>AUSTRALIA 3053	www.immuron.com<br><br> <br><br><br> <br>ABN: 80 063 114 045	Phone: + 61 (0)3 9824 5254<br><br> <br>Facsimile: + 61 (0)3 9822 7735

“Our initial results suggest the inhibitory substance/s in the products are binding to other antigens present on the SARS-CoV-2 virus which interfere with the mechanism the virus uses to gain entry and infect human cells. We do not yet know which compound/s in the products are responsible for this interference. However, we are excited to try and identify them”, said Professor Lyras.

Prof Lyras further added, “it does not matter whether antagonists to the SARS-CoV-2 virus block the binding of the spike protein directly or indirectly as long as they can prevent or reduce infection”.

The research team now plans to try and isolate and identify the inhibitory molecule/s in IMM124E.

The company is also pleased to announce the appointment of Dr Dan Peres as Chief Medical Officer. Dr Peres will be responsible for leading and managing the company’s clinical development programs with a preliminary focus on COVID-19. Dr Peres was previously engaged by Immuron to manage the company sponsored NASH phase II clinical trial.

This release has been authorised by the directors of Immuron Limited.

- - END - - -

COMPANY CONTACT:<br><br> <br>**<br><br> <br>Dr Jerry Kanellos, Ph.D.**<br><br> <br>Chief Executive Officer<br><br> <br>Ph: +61 (0)3 9824 5254<br><br> <br>info@immuron.com

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).

About Travelan®

Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.

About Travelers’ diarrhea

Travelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.

For more information visit: http://www.immuron.com

| Page 2 of 3 |

| --- |

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-lookingstatements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product developmentprograms and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectationsand are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stockvalue. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growthstrategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to theresults of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertaintiesrelating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain keypersonnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent andintellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligationor undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change inour expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Page 3 of 3

Immuron Ltd 6-K, filed May 13, 2021

About this 6-K